In recent years, the terminology related to non-alcoholic fatty liver disease (NAFLD) has undergone significant revision to more accurately reflect its pathophysiological association with metabolic dysfunction. In 2023, the term metabolic dysfunction-associated steatotic liver disease (MASLD) was officially introduced, replacing NAFLD. The updated diagnostic criteria now require the presence of at least one cardiometabolic risk factor. This change not only enhances the clinical definition of the disease but also shifts attention toward its systemic complications.
Growing evidence highlights a significant association between MASLD and chronic kidney disease (CKD). Mechanistically, this relationship is driven by shared pathogenic pathways, including insulin resistance, chronic low-grade inflammation, endothelial dysfunction, and activation of the renin–angiotensin–aldosterone system. Individuals with MASLD are at an increased risk of developing CKD compared to those without metabolically associated hepatic steatosis, even when traditional risk factors are accounted for.
V.W. Wong, M. Ekstedt, G.L. Wong, H. Hagstrom Changing epidemiology, global trends and implications for outcomes of NAFLD J Hepatol, 79 (2023), pp. 842-852
T.H. Karlsen, N. Sheron, S. Zelber-Sagi, P. Carrieri, G. Dusheiko, E. Bugianesi, et al. The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality Lancet, 399 (2022), pp. 61-116
T.K. Chen, D.H. Knicely, M.E. Grams Chronic kidney disease diagnosis and management: a review JAMA, 322 (2019), pp. 1294-1304
C.D. Byrne, G. Targher NAFLD as a driver of chronic kidney disease J Hepatol, 72 (2020), pp. 785-801
А.Mantovani, G. Petracca, G. Beatrice, A. Csermely, A. Lonardo, J.M. Schattenberg, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis Gut, 71 (2022), pp. 156-162
J. Ludwig, T.R. Viggiano, D.B. McGill, B.J. Oh Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc, 55 (1980), pp. 434-438
J. Bilson, Al. Mantovani, Chr. D. Byrne, G. Targher, Steatotic liver disease, MASLD and risk of chronic kidney disease, Diabetes & Metabolism, Volume 50, Issue 1, 2024, 101506, ISSN 1262-3636
M. Eslam, P.N. Newsome, S.K. Sarin, Q.M. Anstee, G. Targher, M. Romero-Gomez, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement J Hepatol, 73 (2020), pp. 202-209
M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature J Hepatol, 78 (2023), pp. 1966-1986
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024;81:492–542.
G. Targher, M. Chonchol, L. Bertolini, S. Rodella, L. Zenari, G. Lippi, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease J Am Soc Nephrol, 19 (2008), pp. 1564-1570
Y. Chang, S. Ryu, E. Sung, H.Y. Woo, E. Oh, K. Cha, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men Metabolism, 57 (2008), pp. 569-576
S. Wei, J. Song, Y. Xie, J. Huang, J. Yang Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes Diabetes Res Clin Pract, 197 (2023), Article 110563
Y. Liang, H. Chen, Y. Liu, X. Hou, L. Wei, Y. Bao, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China J Clin Endocrinol Metab, 107 (2022), pp. 88-97
S.Y. Kwon, J. Park, S.H. Park, Y.B. Lee, G. Kim, K.Y. Hur, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease Sci Rep, 13 (2023), p. 1796
S. Chen, J. Pang, R. Huang, H. Xue, X. Chen Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants Hepatol Int, 17 (2023), pp. 595-605
H. Noels, M. Lehrke, R. Vanholder, J. Jankowski Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations Nat Rev Nephrol, 17 (2021), pp. 528-542
А.Charlton, J. Garzarella, K.A.M. Jandeleit-Dahm, J.C. Jha Oxidative stress and inflammation in renal and cardiovascular complications of diabetes Biology, 10 (2020), p. 18
M. Yang, S. Luo, J. Yang, W. Chen, L. He, D. Liu, et al. Crosstalk between the liver and kidney in diabetic nephropathy Eur J Pharmacol, 931 (2022), Article 175219
А.Mitrofanova, S. Merscher, A. Fornoni Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease Nat Rev Nephrol, 19 (2023), pp. 629-645
S.H. Hammoud, I. AlZaim, Y. Al-Dhaheri, A.H. Eid, A.F. El-Yazbi Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases Front Endocrinol, 12 (2021), Article 707126
L. D'Marco, J. Salazar, M. Cortez, M. Salazar, M. Wettel, M. Lima-Martínez, et al. Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease Kidney Res Clin Pract, 38 (2019), pp. 365-372
X.Y. Qi, S.L. Qu, W.H. Xiong, O. Rom, L. Chang, Z-S. Jiang Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword Cardiovasc Diabetol, 17 (2018), p. 134
T. Arabi, A. Shafqat, B.N. Sabbah, N.A. Fawzy, H. Shah, H. Abdulkader, et al. Obesity-related kidney disease: Beyond hypertension and insulin-resistance Front Endocrinol, 13 (2022), Article 1095211
H. Chen, H. Tan, J. Wan, Y. Zeng, J. Wang, H. Wang, et al. PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets Pharmacol Ther, 245 (2023), Article 108391
Y. Ma, M. Shi, Y. Wang, J. Liu PPARγ and its agonists in chronic kidney disease Int J Nephrol, 2020 (2020), Article 2917474
H. Krukowski, S. Valkenburg, A.M. Madella, J. Garssen, J. vanBergenhenegouwen, S.A. Overbeek, et al. Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential Nat Rev Nephrol, 19 (2023), pp. 87-101
J. Bilson, J.K. Sethi, CD. Byrne Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function Proc Nutr Soc, 81 (2022), pp. 146-161
B.M. Beker, I. Colombo, H. Gonzalez-Torres, C.G. Musso Decreasing microbiota-derived uremic toxins to improve CKD outcomes Clin Kidney J, 15 (2022), pp. 2214-2219
M.V. Salguero, M.A.I. Al-Obaide, R. Singh, T. Siepmann, TL. Vasylyeva Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease Exp Ther Med, 18 (2019), pp. 3461-3469
G. Magliocca, P. Mone, B.R. Di Iorio, A. Heidland, S. Marzocco Short-chain fatty acids in chronic kidney disease: focus on inflammation and oxidative stress regulation Int J Mol Sci, 23 (2022), p. 5354
E. Stavropoulou, K. Kantartzi, C. Tsigalou, T. Konstantinidis, G. Romanidou, C. Voidarou, et al. Focus on the gut-kidney axis in health and disease Front Med, 7 (2020), Article 620102
T.Y. Wang, R.F. Wang, Z.Y. Bu, G. Targher, C.D. Byrne, D.Q. Sun, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease Nat Rev Nephrol, 18 (2022), pp. 259-268
А. Mantovani, C. Zusi PNPLA3 gene and kidney disease Explor Med, 1 (2020), pp. 42-50
А.Mantovani, A. Taliento, C. Zusi, G. Baselli, D. Prati, S. Granata, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings Liver Int, 40 (2020), pp. 1130-1141
А.Mantovani, S. Pelusi, S. Margarita, F. Malvestiti, M. Dell'Alma, C. Bianco, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction Aliment Pharmacol Ther, 57 (2023), pp. 1093-1102
Ръководство по нефрология и бъбречно-заместващо лечение, проф. д-р Светла Стайкова, 2018.
Л. Стоянова, Хиперфилтрацията – рисков фактор за прогресията на бъбречната увреда при различни метаболитни заболявания, Наука Ендокринология, бр. 1/2020 г., стр. 13-17.
